Researchers are asking for tougher penalties and fines for pharmaceutical companies that market drugs for “off label” promotion, according to a new study. Researchers describe ways that the pharmaceutical industry uses marketing to encourage “the unmonitored, potentially dangerous use of drugs by patients for whom risks and benefits are unknown.”